Haleon Pakistan Limited (PSX:HALEON)

Pakistan · Delayed Price · Currency is PKR

682.17

-4.70 (-0.68%)

At close: Nov 6, 2026

Market Cap	79.85B -19.3%
Revenue (ttm)	40.58B -3.1%
Net Income	6.52B +9.3%
EPS	55.66 +9.3%
Shares Out	117.05M
PE Ratio	12.26
Forward PE	11.82
Dividend	30.00 (4.40%)
Ex-Dividend Date	Sep 7, 2026

Volume	13,170
Open	685.90
Previous Close	686.87
Day's Range	675.00 - 685.90
52-Week Range	650.00 - 1,010.00
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Haleon Pakistan

Haleon Pakistan Limited engages in the manufacture, marketing, and sale of pharmaceutical and consumer healthcare products in Pakistan, the Philippines, and Qatar. The company offers oral health, pain relief, wellness and nutrition, and respiratory health products. It sells its products primarily under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, T-Day, ENO, Hydrozole, Qalsium-D, and Voltral Emulgel brands. The company was formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited and changed its name to Haleon Pakistan Limite... [Read more]

Industry Pharmaceutical Preparations

Founded 2015

Employees 451

Stock Exchange Pakistan Stock Exchange

Ticker Symbol HALEON

Full Company Profile

Financial Performance

In 2025, Haleon Pakistan's revenue was 43.11 billion, an increase of 15.86% compared to the previous year's 37.21 billion. Earnings were 6.37 billion, an increase of 39.21%.

Financial Statements